Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Key facts
- Who runs it
- Institute of Tropical Medicine, Belgium
- Where
- Belgium, Burkina Faso, and Mozambique3 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 458 people enrolled
- Started
- 13 Dec 2023
- Ended
- 9 Dec 2025
- Type of study
- Observational, 7 groups
- Record updated
- 11 March 2026
Who can take part
- Age
- 1 year and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age: ≥ 1 year
- Willing and able to provide written informed consent (or assent for minors with written informed consent by parent(s) and/or guardian(s); Pilot:; -symptomatic for P. falciparum; -/Travel to P. falciparum endemic area within the last month; WP1:
- Resident in Nanoro district
- non-symptomatic individuals; WP2:
- Positive for P. falciparum infection via Rapid Diagnostic Tests (RDT)
- Age: ≥ 1 and ≤ 12 years
- Patients are included when suspected of the following conditions:
- Severe malaria by infection with P. falciparum is defined in the presence of P. falciparum asexual parasitemia, and as one or more of the following:
- Impaired consciousness: A Blantyre coma score < 3 (when patients are ≤ 6 years) or Glasgow coma score < 10 (when patients are ≥ 6 years)
- Prostration: Generalized weakness so that the person is unable to sit, stand or walk without assistance
- Multiple convulsions: More than two episodes within 24 hours
- Clinical manifestation of respiratory distress (e.g., rapid, deep and labored breathing)
- Diagnosis through exclusion: absence of an identified alternative cause
- Uncomplicated malaria by infection with P. falciparum is defined as a patient who presents with lethargic profile (e.g. fever) and a positive parasitological test for P. falciparum, but with no features of severe malaria
Who cannot take part
- Previous malaria treatment or prophylaxis in the last week
- Delayed developmental status or history of chronic illness
- Symptoms of malaria, as defined by presence of fever (body temperature >37.5 °C or history of fever during the past 48 hours) with a positive RDT (RDT are performed always when there is presence of fever)
- A questionnaire will be used during the clinical assessment that addresses following exclusion criteria:; x Antimalarial drug treatment or other medication during the past week x If the patient had a meal within 4 hours before admission x Patients with acute meningitis (as clinically evaluated according to the local guidelines) x Patients with developmental delay or history of chronic illness x Vaccination during the past week
- Participation in another study
- Inability or unwillingness of the parents or guardians to provide informed consent; WP1:
- Any plans to leave the study are in the coming 10 days; WP2:
- Severe anemia (will be determined via clinical examination), since blood samples can hardly be withdrawn, co-morbidities
Where is this trial?
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Understanding the sexual conversion of the malaria parasite is essential to interrupt malaria transmission. A new tool is developed that, based on expression analysis of sexual stage biomarkers, will estimate sexual conversion rates in natural infections.
The 7 groups in the trial
- Pilot study Belgium Patients
Patients (P. falciparum-infected) No intervention 6 ml of venous blood sampled at one time point
- Pilot study Belgium Controls
Control non-infected individuals No intervention 6 ml of venous blood sampled at one time point
- Work package 1 Burkina Faso Asymptomatic
Asymptomatic (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point. 300µl of finger prick blood at four follow-up visits 24, and 48 and 72h and day 10 after the enrollment.
- Work package 1 Burkina Faso uncomplicated patients
uncomplicated patients (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point.
- Work package 1 Burkina Faso Uncomplicated Malaria Patients
Control non-infected individuals No intervention Venous blood sample (maximum of 6 ml) at 1 time point.
- Work package 2 Mozambique Uncomplicated malaria patients
Uncomplicated malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.
- Work package 2 Burkina Faso Severe malaria patients
Severe malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 11 March 2026